All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aim, Coeptis, Cytosorbents, Epivax, Intravacc, Intrinsix.
Nearly six months after ditching its phase II/III COVID-19 vaccination study to chase a booster strategy, Inovio Pharmaceuticals Inc. is now ditching the heterologous booster. The decision to stop internally funding INO-4800 as a booster was made after sifting through data on global demand for COVID-19 vaccines, the condition of the market and Inovio’s own portfolio.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Avrobio, Diamedica, Dyadic International, ITM Isotope Technologies München, Myeloid, Novo Nordisk, Reveragen, Santhera, Simcere.
Pfizer Inc. has divulged 3C-like proteinase (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Novacyt, Radiaction, Transit Scientific.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 2seventy, Aquestive, Assertio, BMS, Ignyte, JW, Kissei, Obseva, Obsidian, Peak, Res Nova, Soligenix and Therapeutic Solutions.
RSS
